Business
- US Core CPI Eases in November to Slowest Pace Since 2021 - Underlying US inflation rose from a year earlier at the slowest pace since early 2021 in November. The core consumer price index increased 2.6%, compared with a 3% annual advance two months earlier, while the overall CPI climbed 2.7% in Nov
- U.S. admits liability in Army helicopter collision with American Airlines jet that killed 67 people - The U.S. admitted fault in the deadly Army Black Hawk helicopter collision on Jan. 29 that killed all 67 people on board.
- FCC chief Brendan Carr tells Senate that his agency is 'not formally ... independent' - FCC chairman Brendan Carr testified to a congressional committee for the first time since ABC suspended Jimmy Kimmel's show following a Carr threat.
- The Oscars are heading to YouTube in 2029 - The Academy of Motion Picture Arts and Sciences signed a multi-year deal with Google-owned YouTube to stream the Oscars globally starting in 2029.
- Medical supply firm Medline jumps more than 25% in debut after biggest IPO of 2025 - Medline priced at $29 per share on Tuesday, raising $6.26 billion to cap off a strong year for new listings and bolster optimism about 2026.
- ‘Orwellian’: Ben & Jerry’s founder tells CNBC he’s alarmed by Magnum’s board overhaul - The world's largest standalone ice cream business, Magnum, is only a week old but has already had a lifetime of corporate drama.
- This market's strength lies in the non-tech growth stocks, Jim Cramer says - CNBC's Jim Cramer examined recent market action.
- Hyperscaler AI spending could slow down if Oracle shows 'discipline' - CNBC's Jim Cramer on Tuesday opined on massive AI spending that has hurt tech stocks.
- Kushner's Affinity Partners exits Paramount bid for Warner Bros. Discovery - PoliticsKushner's Affinity Partners exits Paramount bid for Warner Bros. DiscoveryPublished Tue, Dec 16 20254:40 PM ESTUpdated 7 Min AgoDan Mangan@_DanManganEam
- What Trump's reclassification of pot and CBD could mean for seniors, research and stocks - Reclassification to a Schedule III drug and possible Medicare coverage for pot could unlock new investment from pharmaceutical companies.